Market analysis of sedative and hypnotic drugs used in anesthesia

Sedative hypnotics is a kind of drugs which can inhibit the function of central system and play a role of sedation and hypnosis It is mainly used to treat insomnia, schizophrenia, anticonvulsion, sedation, etc Because this kind of drugs can make the cerebral cortex slightly inhibited, make the patient produce sedation, relieve anxiety, tension, and often used in clinical anesthesia Sedative and hypnotic drugs can be used as auxiliary anesthetics On the one hand, they can be given before anesthesia to reduce the mental burden of patients before operation; on the other hand, they can be used as anesthetics inducers to improve the convulsion threshold of anesthetics and reduce the dosage of anesthetics; on the other hand, they can also be used for postoperative sedation and relieve the postoperative dryness caused by the residues of general anesthetics and muscle relaxants The main types of sedative hypnotics are barbiturates, benzodiazepines and others Market analysis of sedative and hypnotic drugs 1 According to the data of China Pharmaceutical Industry Information Center, the market of sedative and hypnotic drugs in sample hospitals of national key cities grew rapidly in 2010-2016, with an average compound growth rate of 35% in recent years In 2016, the sales volume of sample hospitals was 720 million yuan, and the national market was estimated to be about 2.2 billion yuan Such a rapid growth rate is not only a contribution of anesthesia auxiliary drugs, but may be related to the continuous increase in the number of insomnia caused by work stress and pressure in recent years The sedative and hypnotic drugs used for anesthesia in China mainly include barbiturates, benzodiazepines and non benzodiazepines Because barbiturates are prone to serious adverse reactions such as dependence and withdrawal symptoms, the frequency of use of new sedative and hypnotic drugs is getting lower and lower with the continuous listing and widespread use of them, which has gradually withdrawn from the stage of history From the domestic sales data, at present, the mainstream drugs are mainly benzodiazepines and non benzodiazepines, among which dexmedetomidine, the adrenaline receptor agonist in non benzodiazepines, is the first, and midazolam, the benzodiazepines, is the second, accounting for nearly 85% of the whole sedative and hypnotic market 2 Main variety 1: dexmedetomidine was developed by Orion Pharma (Finland) Co., Ltd and abott (USA) Co., Ltd in December 1999, FDA approved it for short-term sedation (no more than 24 hours) during tracheal intubation and ventilator use in intensive care patients In 2008, FDA approved it for sedation of non intubated patients before and / or during surgery and other procedures In 2009, Jiangsu Hengrui was approved to be listed in China as the first imitated enterprise Dexmedetomidine, as a highly selective α 2 receptor agonist, has a unique type of sedation, i.e "conscious sedation" Patients seem to be sleeping, but they are easy to wake up In addition, it hardly causes respiratory depression and can be safely used in patients with mechanical ventilation and spontaneous respiration These characteristics make dexmedetomidine a very useful drug for early extubation and fast channel cardiac anesthesia Since its listing, the domestic sales of youmeituomi has grown rapidly The sales of sample hospitals have soared to 500 million yuan from 21 million yuan in the first year after listing to 2016 At present, there are four domestic approved enterprises of the drug, but more than 90% of the market is still in the hands of Jiangsu Hengrui, the first imitation enterprise 3 Main product 2: midazolam midazolam belongs to benzodiazepine, which is usually used for preoperative sedation It is characterized by quick onset, short duration, no drug resistance, withdrawal symptoms or rebound It is widely used in clinical anesthesia and has basically replaced diazepam, temazepam and other drugs However, the biggest adverse effect is that it will produce respiratory inhibition When combined with anesthetics and analgesics, it will increase the intensity of respiratory inhibition Therefore, it is forbidden to use ventilator in the elderly and ICU Compared with dexmedetomidine, the growth rate is relatively slow In 2016, the sales volume of sample hospitals was 100 million yuan, ranking second in sedative and hypnotic drugs Among the approved domestic manufacturers of midazolam, there are 4 raw materials, 3 injections and 1 tablet 95% of the market is exclusively owned by Jiangsu Enhua 4 It is expected that sedative and hypnotic drugs, as auxiliary anesthetics, are a smaller branch of anesthetics At present, dexmedetomidine, the main product, has become the first-line drug for preoperative sedation due to its good safety and few adverse reactions, occupying 70% of the market for sedative and hypnotic drugs There will still be a huge growth space in the future, and Jiangsu Hengrui will continue to benefit from this product The adverse reactions of midazolam, especially respiratory depression, may limit its clinical application, and the market growth space is limited.